Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)
| Market Cap | 2.25B+46.6% |
| Revenue (ttm) | 959.90M+24.3% |
| Net Income | 181.27M+0.2% |
| EPS | 3.08-0.6% |
| Shares Out | 57.89M |
| PE Ratio | 12.44 |
| Forward PE | 8.97 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 178,818 |
| Open | 39.14 |
| Previous Close | 39.34 |
| Day's Range | 38.71 - 39.21 |
| 52-Week Range | 25.52 - 43.49 |
| Beta | 1.01 |
| Analysts | Buy |
| Price Target | 49.00(+26.35%) |
| Earnings Date | Nov 3, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About HRMY
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$HRMY stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in HRMY holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by HRMY's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
HRMY Estimated quarterly lobbying spending
Source: U.S. Senate LDA
HRMY Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Net product revenue | $261.28M | 78.22% |
| Cost of product sold | $63.19M | 18.92% |
| Stock-based compensation | $9.58M | 2.87% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New HRMY patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to HRMY from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in HRMY
| ETF | Est. Holding Size |
|---|---|
| IJRiShares Core S&P Small-Cap ETF | $116.40M |
| AVUVAvantis U.S. Small Cap Value ETF | $104.11M |
| AFTYPacer CSOP FTSE China A50 ETF | $64.11M |
| VTIVanguard Morningstar Total Stock Market ETF | $61.30M |
| IWMiShares Russell 2000 ETF | $46.63M |
| VBVanguard Morningstar Small-Cap ETF | $44.53M |
Estimated from each fund’s disclosed top holdings × AUM
HRMY Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from HRMY’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score